Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences

Biochem Pharmacol. 1992 Feb 4;43(3):650-4. doi: 10.1016/0006-2952(92)90592-7.

Abstract

The recombinant plasmid pBHIV1 carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1), linked to the chloramphenicol acetyl transferase (CAT) gene, was introduced into human and rat fibroblasts. Stable transfectants resistant to geneticin expressed CAT activity from the HIV-1 LTR. It was found that the cytotoxic drug cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) at concentrations from 1 x 10(-6) to 1 x 10(-4) M does not stimulate the expression of CAT from the HIV-1 LTR. These results differ from previous studies with the related drug cis-diamminedichloroplatinum(II) which showed stimulation of gene expression from the HIV-1 LTR and suggest that carboplatin could be used in the treatment of cancer patients with Acquired Immune Deficiency Syndrome.

Publication types

  • Comparative Study

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Animals
  • Carboplatin / pharmacology*
  • Carboplatin / therapeutic use
  • Carboplatin / toxicity
  • Cell Division / drug effects
  • Chloramphenicol O-Acetyltransferase / biosynthesis*
  • Cisplatin / pharmacology*
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Gene Expression Regulation, Enzymologic / drug effects*
  • HIV Long Terminal Repeat / drug effects*
  • HIV Long Terminal Repeat / genetics
  • Humans
  • Rats
  • Transfection

Substances

  • Carboplatin
  • Chloramphenicol O-Acetyltransferase
  • Cisplatin